Methazolamide

Generic Name: Methazolamide

Drug Type: Small Molecule

Chemical Formula: C_₅H_₈N_₄O_₃S_₂

CAS Number: 554-57-4

Unique Ingredient Identifier: W733B0S9SD

Overview

A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.

Indication

For treatment of chronic open-angle glaucoma and acute angle-closure glaucoma

Associated Conditions

Acute angle-closure glaucoma
Open Angle Glaucoma (OAG)

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Acamprosate and Methazolamide for Essential Tremor	2024/03/15	NCT06312800	Phase 2	Withdrawn	Henry Ford Health System
Effect of Acetazolamide and Methazolamide on Hypoxic Exercise Performance	2022/10/12	NCT05575180	Phase 4	Completed	University of Waterloo
Use of Methazolamide to Lower Intraocular Pressure	2022/08/11	NCT05498103	Phase 4	Active, not recruiting	University of Colorado, Denver
AZ, MZ, and the Pulmonary System Response to Hypoxia	2016/05/03	NCT02760121	Phase 4	Completed	University of British Columbia
Muscle Fatigue and Carbonic Anhydrase Inhibitors	2016/05/02	NCT02758470	Phase 4	Completed	University of British Columbia
Three New Ideas to Protect Special Forces From the Stress of High Altitude	2015/06/04	NCT02463357	Phase 4	Completed	University of Colorado, Denver
Stop Retinal Ganglion Cell Dysfunction Study	2015/03/17	NCT02390284	Phase 3	Completed	University of Miami
Rapid Acclimatization to Hypoxia at Altitude	2012/10/05	NCT01702025	Phase 1	Completed	Colorado State University
Safety Evaluation of Aminophylline and Methazolamide	2012/04/27	NCT01587027	Phase 1	Completed	Poudre Valley Health System
Improving Tumor Oxygenation in Cervical Cancer	2005/11/23	NCT00257829	Phase 2	Withdrawn	University of California, Irvine

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
methazolamide	Padagis US LLC	0574-0791	ORAL	50 mg in 1 1	12/10/2021
methazolamide	Effcon Laboratories, Inc.	55806-021	ORAL	25 mg in 1 1	1/9/2024
Methazolamide	ANI Pharmaceuticals, Inc.	62559-240	ORAL	25 mg in 1 1	5/12/2017
methazolamide	A-S Medication Solutions	50090-3233	ORAL	50 mg in 1 1	11/12/2018
Methazolamide	Bryant Ranch Prepack	63629-1987	ORAL	50 mg in 1 1	5/12/2017
Methazolamide	TAGI Pharma, Inc.	51224-124	ORAL	50 mg in 1 1	3/23/2023
Methazolamide	Bryant Ranch Prepack	63629-1986	ORAL	25 mg in 1 1	5/12/2017
methazolamide	Effcon Laboratories, Inc.	55806-020	ORAL	50 mg in 1 1	1/9/2024
Methazolamide	Bryant Ranch Prepack	72162-1754	ORAL	25 mg in 1 1	5/12/2017
methazolamide	Padagis US LLC	0574-0790	ORAL	25 mg in 1 1	12/10/2021

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
NEPTAZANE TABLETS 25MG	wyeth-ayerst canada inc.	02238070	Tablet - Oral	25 MG	7/24/1998
NEPTAZANE TABLETS 50MG	wyeth-ayerst canada inc.	02238071	Tablet - Oral	50 MG	12/23/1998
METHAZOLAMIDE	aa pharma inc	02245882	Tablet - Oral	50 MG	7/25/2002
NEPTAZANE TABLETS 25MG USP	storz, division of wyeth-ayerst canada inc.	02019604	Tablet - Oral	25 MG	12/31/1995
NEPTAZANE TABLETS 50MG	storz, division of wyeth-ayerst canada inc.	02022389	Tablet - Oral	50 MG	12/31/1993

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Glaucoma Drug Methazolamide Shows Promise in Reducing Tau Buildup Linked to Alzheimer's

9 months ago

Researchers found that methazolamide, a glaucoma drug, effectively clears tau protein buildup in zebrafish models of tauopathies.

Glaucoma Drug Methazolamide Shows Promise in Reducing Tau Protein Toxicity Linked to Dementia

9 months ago

Researchers found that carbonic anhydrase (CA) inhibitors, particularly methazolamide, significantly reduced tau protein levels in animal models.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.